ABLIS logo

Abliva BATS-CHIXE:ABLIS Stock Report

Last Price

SEK 0.33

Market Cap

SEK 240.3m

7D

0%

1Y

n/a

Updated

15 Apr, 2023

Data

Company Financials +

Abliva AB (publ)

BATS-CHIXE:ABLIS Stock Report

Market Cap: SEK 240.3m

ABLIS Stock Overview

Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. More details

ABLIS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Abliva AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Abliva
Historical stock prices
Current Share PriceSEK 0.33
52 Week HighSEK 0.33
52 Week LowSEK 0.33
Beta1.16
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-58.42%
5 Year Change-85.56%
Change since IPO-93.97%

Recent News & Updates

Recent updates

Shareholder Returns

ABLISGB BiotechsGB Market
7D0%-4.2%-2.6%
1Yn/a-24.5%2.4%

Return vs Industry: Insufficient data to determine how ABLIS performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how ABLIS performed against the UK Market.

Price Volatility

Is ABLIS's price volatile compared to industry and market?
ABLIS volatility
ABLIS Average Weekly Movementn/a
Biotechs Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: ABLIS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ABLIS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20007Ellen Donnellyabliva.com

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments.

Abliva AB (publ) Fundamentals Summary

How do Abliva's earnings and revenue compare to its market cap?
ABLIS fundamental statistics
Market capSEK 240.31m
Earnings (TTM)-SEK 85.26m
Revenue (TTM)SEK 31.00k

7,752x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABLIS income statement (TTM)
RevenueSEK 31.00k
Cost of RevenueSEK 68.30m
Gross Profit-SEK 68.27m
Other ExpensesSEK 17.00m
Earnings-SEK 85.26m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

May 23, 2023

Earnings per share (EPS)-0.081
Gross Margin-220,216.13%
Net Profit Margin-275,038.71%
Debt/Equity Ratio0%

How did ABLIS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/15 20:51
End of Day Share Price 2023/01/16 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abliva AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Markets
Jonas PeciulisEdison Investment Research
Ludvig SvenssonPenser Access